DPYD Recombinant Monoclonal Antibody

1. This study reports novel and rare genetic variants underlying DPD deficiency in 9 cancer patients presenting with severe fluoropyrimidine-associated toxicity. PMID: 28024938
2. TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD was not associated with susceptibility to CRC. However, the 2R/2R and 2R/3R genotypes of TYMS polymorphism could significantly contribute to hematological and gastric toxicity in CRC patients in this sample populatio PMID: 29906295
3. Results still showed UGT1A1*6 and UGT1A1*28 to be partially associated with irinotecan-induced toxicity and clinical response. An examination of more UGT1A loci, except for UGT1A1*6 and UGT1A1*28, was not helpful to improve the predictive value of irinotecan-based toxicity and efficacy. An examination of DPYD*5 assisted in the prediction of severe diarrhea. PMID: 28637434
4. The present study suggests that the SNP rs1801160 and the "IISt" haplotype in the DPYD gene may also have a role in colorectal cancer risk. PMID: 29372689
5. Low DPYD expression is associated with colorectal cancer. PMID: 28929491
6. *6 rs1801160 and *2A rs3918290 DPYD variant alleles were significantly associated with time to neutropenia in colon cancer. PMID: 29065426
7. Results have shown crosstalk among the EGFR cascade and Sp1 and DPD expressions in EGFR mutant non-small-cell lung cancer cell lines. EGF-induced Sp1 up-regulation resulted in both DPYD mRNA and DPD protein expressions. PMID: 27268079
8. Carriers of the rare allelic variants DPYD*2A, DPYD*13, and DPYD D949V are more likely to experience severe adverse reactions during fluoropyrimidine-based therapy. PMID: 28614820
9. Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3-4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V PMID: 28481884
10. Combined expression analyses of hENT1, TS, and DPD may predict long-term outcomes in patients with borderline resectable pancreatic cancer after neoadjuvant chemoradiotherapy PMID: 28476815
11. We demonstrated that real-time DPYD genotyping using TaqMan probes is cost effective in all fluoropyrimidine-based treatments PMID: 27248859
12. In pancreatic neuroendocrine neoplasms, biochemical response (p = 0.005) and high dihydropyrimidine-dehydrogenase expression (p = 0.018) were predictive markers of response to 5-FU-based chemotherapy. Thymidylate-Synthase deficiency was an independent risk factor for shorter progression-free survival. PMID: 28027897
13. ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer. PMID: 27741011
14. this study was to identify potential risk variants in DPYP gene in an understudied East African population as predictors of severe adverse toxicity to 5-FU PMID: 27727460
15. Fourteen out of 275 cancer patients (5.1%) carried a DPYD variant and received a 25-50% dose reduction recommendation for 5-fluorouracil or capecitabine. None of the patients with a DPYD variant treated with a reduced dose developed toxicities. PMID: 27181275
16. findings showed that almost 57.1% of Chinese colorectal cancer patients had at least one variant of DPYD*5A and DPYD*9A PMID: 27461651
17. High levels of intratumoral DPD expression have a negative impact on sensitivity to 5-fluorouracil in gastric cancer patients, but no prognostic value for long-term survival was uncovered. (Meta-analysis) PMID: 28255193
18. Reprot strong functional effect of a DPYD haplotype upon a phenotypic marker of individual 5-FU metabolism to improve toxicity prediction. PMID: 26216193
19. we believe that developing functional testing at the bedside could probably help to better picture the actual DPD status of patients scheduled for fluorouracil-based therapy, so as to propose subsequent appropriate adaptive dosing strategies. PMID: 27281624
20. DPYD genotyping for alleles 7, *2A, *13 and Y186C was not helpful in the identification of patients with severe DPD deficiency in this series of patients PMID: 27399164
21. Our results revealed that the C allele of the DPYD 85T > C polymorphism might be associated with susceptibility to pediatric acute lymphoblastic leukemia PMID: 26846104
22. Increases in gene expression levels of TYMP, DPYD, and HIF1A in tumor tissues at 7 days after the start of CRT may be useful for predicting the efficacy of CRT including S-1 or UFT PMID: 27127154
23. There were not statistical significant differences between carriers of KRAS mutated alleles between SD and PD groups. No significant difference was found between response rates and toxicity and DPD or UGT1A1 genotypes. Our results suggested that determination of DPD or UGT1A1 genotypes could not be useful for predicting severe toxicity of irinotecan in our population. PMID: 27072236
24. Study shows that somatic mutations of DPYD cause a switch in pyrimidine metabolism and promote gene expression of pyrimidine enzymes toward malignant progression. PMID: 26609109
25. Results suggest that DPYD c.1129-5923 C>G/hapB3 have limited predictive value for severe toxicity to 5-FU based combination chemotherapy. PMID: 26658227
26. oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels; bevacizumab induces VEGFA expression in metastatic colorectal cancer PMID: 26372896
27. This study demonstrates the clinical validity of combined MIR27A/DPYD screening to identify patients at risk of severe FP-toxicity. PMID: 26804235
28. The expression of dihydropyrimidine dehydrogenase and its correlation with survival in stage II/III gastric cancer patients PMID: 25112781
29. We propose the gene activity score for translating DPYD genotype into phenotype--{REVIEW} PMID: 26265346
30. Demonstrate a correlation between occurrence of DPYD gene variant c.496A>G and KRAS wild type status of colorectal cancer tissue. PMID: 26281864
31. Single nucleotide polymorphisms (SNPs) in Dihydropyrimidine Dehydrogenase and UGT1A1 influence fluoropyrimdines and irinotecan adverse events (AEs). PMID: 25782327
32. The relationship between DPD genotype and dihydrouracil/uracil values in the 22 patients of the present study was significant PMID: 26265035
33. DPYD variants c.1679T>G and c.1236G>A/HapB3 are clinically relevant predictors of fluoropyrimidine-associated toxicity. PMID: 26603945
34. The dihydropyrimidine dehydrogenase and ERCC1 expression profile could potentially serve as a useful prognostic biomarker and therapeutic target for surgically resected patients with ampullary carcinoma. PMID: 25906447
35. miR-494 is directly bound to DPYD 3'UTR and negatively regulated DPYD expression in colon cancer. PMID: 25873402
36. results suggest that the baseline 5,6-dihydrouracil:uracil plasma ratio in most individuals reflects the nonsaturated state of DPD and is not predictive of decreased DPD activity PMID: 25410891
37. genome-wide association studies in women of European ancestry: Data confirm that SNPs in DPYD (rs11587873, rs828054) are associated with ovarian carcinoma; analyses included over 36,000 women contributing DNA in the Ovarian Cancer Assoc Consortium. PMID: 25066213
38. Germline polymorphism of DPYD have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for metastatic gastrointestinal malignancies. PMID: 25677447
39. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor and response to chemotherapy. PMID: 24405586
40. In patients with heterozygous DPD IVS14+1 mutation, 5-FU dose should be appropriately reduced according to last plasma concentration to reduce adverse reactions, while the homozygous ones should avoid application of 5-FU and its derivatives. PMID: 24817302
41. DPYD harbours rare and common capecitabine toxicity variants PMID: 24647007
42. Pre-therapeutic DPYD testing may prevent 20-30% of life-threatening or lethal episodes of fluoropyrimidine toxicity in Caucasian patients PMID: 24923815
43. Taken together, these results suggest that miR-27a and miR-27b expression may be pharmacologically relevant modulators of Dihydropyrimidine dehydrogenase enzyme function in the liver. PMID: 24401318
44. We suggest that a chip including DPYD, TYMS, TYMP, TK1, and TK2 genes is a potential tool to predict response in LARC following fluoropyrimidine-based CCRT. PMID: 24455740
45. Colorectal tumors, deficient in mismatch repair, overexpress thymidylate synthetase and dihydropyrimidine dehydrogenase. PMID: 24800948
46. Association between flurouracil toxicity and DPYD missense mutations. PMID: 24648345
47. DPD is involved in the survival of human embryo brain-derived cells in culture. There was a a reversed correlation between the activities of XO and DPD over 12 days under normal conditions as well as in the presence of XO and DPD inhibitors. PMID: 23597150
48. Of 36 previously assessed polymorphisms, only four-TYMS 5'VNTR 2R/3R, TYMS 3'UTR 6bpins-del, DPYD 2846TA, and DPYD *2A-were formally associated with global G3+ toxicity in our analysis. Associations were only present in fluorouracil monotherapy regimens. PMID: 24590654
49. DPYD*5 and 1896 T>C accounted for 29.9% of the occurrences of neutropenia (analysis of variance, P = 0.017). PMID: 23942539
50. One nonsynonymous SNP of Dihydropyrimidine dehydrogenase (+199381A > G, Asn151Asp) was predicted to change its polarity of amino acid (Asn, neutral to Asp, negative). PMID: 23960437

Show More

Hide All

HGNC: 3012

OMIM: 274270

KEGG: hsa:1806

STRING: 9606.ENSP00000359211

UniGene: Hs.335034